Allurion Technologies (ALUR) Projected to Post Earnings on Wednesday

Allurion Technologies (NYSE:ALUR) is expected to announce its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.34) per share and revenue of $3.10 million for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 8:30 AM ET.

Allurion Technologies Trading Down 12.9%

Shares of Allurion Technologies stock opened at $0.69 on Wednesday. The company has a fifty day simple moving average of $0.77 and a 200-day simple moving average of $1.26. Allurion Technologies has a 12-month low of $0.23 and a 12-month high of $3.42. The stock has a market cap of $10.31 million, a price-to-earnings ratio of -0.07 and a beta of -0.18.

Institutional Trading of Allurion Technologies

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd lifted its stake in shares of Allurion Technologies by 43.2% in the second quarter. XTX Topco Ltd now owns 18,670 shares of the company’s stock valued at $45,000 after purchasing an additional 5,633 shares during the period. State Street Corp lifted its stake in shares of Allurion Technologies by 76.2% in the fourth quarter. State Street Corp now owns 26,135 shares of the company’s stock valued at $32,000 after purchasing an additional 11,300 shares during the period. Hudson Bay Capital Management LP acquired a new stake in shares of Allurion Technologies in the fourth quarter valued at about $74,000. Heights Capital Management Inc. acquired a new stake in shares of Allurion Technologies in the fourth quarter valued at about $74,000. Finally, Armistice Capital LLC acquired a new stake in shares of Allurion Technologies in the fourth quarter valued at about $74,000. Institutional investors and hedge funds own 21.39% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on ALUR. Weiss Ratings reiterated a “sell (e+)” rating on shares of Allurion Technologies in a research report on Wednesday, January 21st. Chardan Capital set a $3.00 price target on shares of Allurion Technologies and gave the company a “buy” rating in a research report on Tuesday, February 24th. Finally, Loop Capital set a $3.00 price objective on shares of Allurion Technologies in a research report on Tuesday, February 24th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Allurion Technologies presently has an average rating of “Hold” and a consensus target price of $3.00.

About Allurion Technologies

Allurion Technologies is a medical technology company specializing in non-surgical weight-loss solutions. The company’s flagship product, the Allurion Gastric Balloon, is a swallowable, fluid-filled device designed to promote weight loss by creating a sense of fullness in the stomach. Unlike traditional intragastric balloons, the Allurion device does not require endoscopic insertion or removal, as it self-deflates and is naturally expelled after treatment, simplifying the patient experience and reducing clinical resource requirements.

In addition to its gastric balloon, Allurion has developed a comprehensive digital health platform that integrates wireless tracking devices, a mobile application, and remote coaching to support patients throughout their weight-loss journey.